SCYNEXIS, Inc.
$1.07
▼
-0.05%
2026-04-21 09:20:00
www.scynexis.com
NCM: SCYX
Explore SCYNEXIS, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$47.85 M
Current Price
$1.07
52W High / Low
$1.31 / $0.56
Stock P/E
—
Book Value
$1.13
Dividend Yield
—
ROCE
-30.16%
ROE
-16.48%
Face Value
—
EPS
$-0.17
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
18
Beta
1.15
Debt / Equity
4.41
Current Ratio
7.04
Quick Ratio
7.04
Forward P/E
-3.03
Price / Sales
2.17
Enterprise Value
$6.81 M
EV / EBITDA
—
EV / Revenue
0.33
Rating
None
Target Price
$3.47
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Universe Pharmaceuticals INC | $3.32 | — | $1.9 M | — | -5.19% | -7.23% | $11 / $2 | $99.64 |
| 2. | China Pharma Holdings, Inc. | $0.67 | — | $26.84 M | — | -46.43% | -20.91% | $2.6 / $0.5 | $1.47 |
| 3. | United Therapeutics Corporation | $578.37 | 20.76 | $25.34 B | — | 20.73% | 19.71% | $607.89 / $272.12 | $162.6 |
| 4. | TherapeuticsMD, Inc. | $2.19 | 83.93 | $25.35 M | — | -12.82% | -2.41% | $2.95 / $0.95 | $2.32 |
| 5. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 6. | Shuttle Pharmaceuticals Holdings, Inc. | $0.99 | — | $5.7 M | — | -791.36% | -7.91% | $11.25 / $0.5 | $1.13 |
| 7. | Elanco Animal Health Incorporated | $22.34 | — | $11.2 B | — | 2.14% | -3.67% | $27.72 / $8.02 | $13.17 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 18.65 M | 0.33 M | 1.36 M | 0.26 M | 0.98 M | — |
| Operating Profit | 10.52 M | -8.4 M | -9.56 M | -8.61 M | -8.05 M | — |
| Net Profit | 12.26 M | -8.59 M | -6.88 M | -5.39 M | -4.43 M | — |
| EPS in Rs | 0.27 | -0.19 | -0.15 | -0.12 | -0.1 | -0.06 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 20.6 M | 3.75 M | 140.14 M | 5.09 M |
| Operating Profit | -16.07 M | -37.12 M | 72.67 M | -85.76 M |
| Net Profit | -8.61 M | -21.29 M | 67.04 M | -62.81 M |
| EPS in Rs | -0.19 | -0.48 | 1.5 | -1.41 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 59.03 M | 90.64 M | 128.41 M | 87.81 M |
| Total Liabilities | 9.65 M | 35.57 M | 55.45 M | 84.58 M |
| Equity | 49.38 M | 55.08 M | 72.96 M | 3.23 M |
| Current Assets | 40.37 M | 72.18 M | 102.12 M | 79.06 M |
| Current Liabilities | 5.73 M | 24.1 M | 16.3 M | 17.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.28 M | -24.01 M | 60.16 M | -79.88 M |
| Investing CF | 24.31 M | 6.15 M | -34.88 M | -27.39 M |
| Financing CF | -14.17 M | -0.14 M | -36.72 M | 48.6 M |
| Free CF | -5.28 M | -24.01 M | 60.16 M | -79.89 M |
| Capex | — | — | — | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -97.33% | 2652.72% | — | — |
| Earnings Growth % | -131.75% | 206.74% | — | — |
| Profit Margin % | -568.29% | 47.84% | -1233.73% | — |
| Operating Margin % | -990.84% | 51.85% | -1684.48% | — |
| Gross Margin % | 100% | 88.85% | 87.66% | — |
| EBITDA Margin % | -542.15% | 50.58% | -1212.04% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.